The onset of skin and gastrointestinal disorders induced by anti‐CTLA‐4 monotherapy tends to be earlier than that induced by anti‐PD‐1 monotherapy, such as within the first 3–5 weeks of treatment.32 Here, PDCD1 is linked to digestive system disorder.